Mark W Hermonat

Title: Mark W Hermonat: Innovator in Anticancer Agents

Introduction

Mark W Hermonat is a notable inventor based in Mississauga, Canada. He has made significant contributions to the field of cancer research through his innovative work on anticancer agents. His research focuses on developing compounds that can effectively target cancer cells while minimizing side effects.

Latest Patents

Mark W Hermonat holds a patent for "Aminoalkyl ethers of phenols as anticancer agents for the breast." This patent describes the use of N,N-dialkyl-2-[(4-phenylmethyl)phenoxy]ethanamine and N-morpholino-2-[(4-phenylmethyl)phenoxy]ethanamine compounds and their salts as anticancer agents. These compounds have been shown to bind significantly to anti-estrogen binding sites while exhibiting poor binding to estrogen receptor sites. Furthermore, they demonstrate cytotoxic effects on cancer cells. Compositions that include mixtures of these ethanamine compounds with therapeutically active anticancer compounds, such as tamoxifen, have been found to be particularly beneficial.

Career Highlights

Mark W Hermonat is affiliated with the University of Manitoba, where he continues to advance his research in the field of cancer therapeutics. His work has garnered attention for its potential to improve treatment options for breast cancer patients.

Collaborations

Mark has collaborated with Lorne J Brandes, contributing to the development of innovative solutions in cancer treatment. Their partnership has focused on enhancing the efficacy of anticancer agents.

Conclusion

Mark W Hermonat's contributions to the field of cancer research highlight his dedication to improving therapeutic options for patients. His innovative work on anticancer agents demonstrates the potential for significant advancements in cancer treatment.